A Rare Case of Evolocumab Induced Atrial Fibrillation
2021 ◽
Vol 04
(10)
◽
pp. 01-01
Keyword(s):
Evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) is a novel low-density lipoprotein (LDL) lowering agent that has been recently approved by the FDA to reduce the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease, alone or in combination with other lipid-lowering agents, and for treatment of patients with primary hyperlipidemia including familial hypercholesterolemia
2002 ◽
Vol 89
(1)
◽
pp. 67-69
◽
2002 ◽
Vol 57
(5)
◽
pp. M333-M335
◽
2020 ◽
Vol 75
(11)
◽
pp. 2080
◽
2002 ◽
Vol 90
(2)
◽
pp. 147-149
◽
2018 ◽
Vol Volume 14
◽
pp. 2425-2435
◽
2020 ◽
Vol 75
(11)
◽
pp. 44
1998 ◽
Vol 82
(5)
◽
pp. 668-669
◽
2014 ◽
Vol 113
(1)
◽
pp. 17-22
◽
2019 ◽
Vol 124
(3)
◽
pp. 386-404
◽